Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer.
Gleason score (GS)
high-volume mCRPC
overall survival (OS)
taxane
Journal
Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
17
02
2022
accepted:
06
06
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
13
9
2022
Statut:
ppublish
Résumé
Several therapeutic agents are available for metastatic castration-resistant prostate cancer (CRPC). However, prognosis is still not well developed. The Gleason score (GS) is a prognostic factor available for patients with metastatic CRPC. GSs ranging from 6 to 10 and GSs ≥8 are usually categorized as single prognostic factors. In this study, we evaluated the prognosis of high-GS metastatic CRPC in Japanese men. Overall, 105 patients with metastatic CRPC with a GS ≥8 were retrospectively analyzed. Multivariate analyses of patient age, GS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) were performed using Cox proportional hazards analysis to predict overall survival (OS). GS 8 had all Gleason patterns of 4+4. Thirty patients (28.6%) had GS of 8, and 75 (71.4%) had GS of 9 or 10. As a first-line treatment for metastatic CRPC, 42 patients (40%) received abiraterone, 35 (33.3%) received enzalutamide, and 26 (24.8%) received docetaxel. The 5-year OS in patients with GS of 8 was 65.0% [95% confidence interval (CI): 43.07-86.82%], while the 5-year OS in patients with GS of 9 or 10 was 37.0% (95% CI: 24.41-56.11%). There was a significant difference in OS between the GS 8 and GS 9-10 groups (log-rank test, P=0.038). Multivariate analysis showed that GS and ECOG-PS were significant prognostic factors for OS. Patients with metastatic CRPC with GS 9-10 had poor prognoses, suggesting the need for additional treatment options.
Sections du résumé
Background
UNASSIGNED
Several therapeutic agents are available for metastatic castration-resistant prostate cancer (CRPC). However, prognosis is still not well developed. The Gleason score (GS) is a prognostic factor available for patients with metastatic CRPC. GSs ranging from 6 to 10 and GSs ≥8 are usually categorized as single prognostic factors. In this study, we evaluated the prognosis of high-GS metastatic CRPC in Japanese men.
Methods
UNASSIGNED
Overall, 105 patients with metastatic CRPC with a GS ≥8 were retrospectively analyzed. Multivariate analyses of patient age, GS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) were performed using Cox proportional hazards analysis to predict overall survival (OS).
Results
UNASSIGNED
GS 8 had all Gleason patterns of 4+4. Thirty patients (28.6%) had GS of 8, and 75 (71.4%) had GS of 9 or 10. As a first-line treatment for metastatic CRPC, 42 patients (40%) received abiraterone, 35 (33.3%) received enzalutamide, and 26 (24.8%) received docetaxel. The 5-year OS in patients with GS of 8 was 65.0% [95% confidence interval (CI): 43.07-86.82%], while the 5-year OS in patients with GS of 9 or 10 was 37.0% (95% CI: 24.41-56.11%). There was a significant difference in OS between the GS 8 and GS 9-10 groups (log-rank test, P=0.038). Multivariate analysis showed that GS and ECOG-PS were significant prognostic factors for OS.
Conclusions
UNASSIGNED
Patients with metastatic CRPC with GS 9-10 had poor prognoses, suggesting the need for additional treatment options.
Identifiants
pubmed: 36093511
doi: 10.21037/tcr-22-375
pii: tcr-11-08-2681
pmc: PMC9459578
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2681-2687Informations de copyright
2022 Translational Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-375/coif). The authors have no conflicts of interest to declare.
Références
Clin Cancer Res. 2015 Feb 15;21(4):795-807
pubmed: 25691773
Front Oncol. 2022 Mar 10;12:865350
pubmed: 35372068
Transl Androl Urol. 2021 Jul;10(7):3199-3207
pubmed: 34430422
Eur Urol Focus. 2018 Jan;4(1):121-127
pubmed: 29162421
BJU Int. 2013 May;111(5):753-60
pubmed: 23464824
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
J Urol. 1974 Jan;111(1):58-64
pubmed: 4813554
BJU Int. 2020 May;125(5):702-708
pubmed: 31833179
Cancer. 1988 Jan 1;61(1):195-202
pubmed: 3334948
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e335-44
pubmed: 21645976
J Urol. 2010 Feb;183(2):433-40
pubmed: 20006878
Cent European J Urol. 2020;73(2):146-151
pubmed: 32782833
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Asian J Androl. 2021 Mar-Apr;23(2):163-169
pubmed: 33159024
JCO Precis Oncol. 2019;3:
pubmed: 31650100
Eur Urol. 2019 Jan;75(1):35-41
pubmed: 30554605
Clin Genitourin Cancer. 2018 Aug;16(4):e777-e784
pubmed: 29550200
Int J Clin Oncol. 2020 May;25(5):912-920
pubmed: 31919691
BJU Int. 2016 Nov;118(5):763-769
pubmed: 27009882
Am J Surg Pathol. 2016 Oct;40(10):1400-6
pubmed: 27379821
Asian Pac J Cancer Prev. 2019 Mar 26;20(3):661-666
pubmed: 30909661
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414